Eli Lilly and Company (NYSE:LLY) Trading 3% Higher – What’s Next?

Eli Lilly and Company (NYSE:LLY) shares were up 3% on Tuesday . The stock traded as high as $1,021.80 and last traded at $1,017.6770. Approximately 3,712,995 shares traded hands during mid-day trading, an increase of 16% from the average daily volume of 3,191,409 shares. The stock had previously closed at $988.09.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly is drawing bullish attention for its leadership in the obesity and diabetes market, with several articles highlighting continued revenue momentum from Mounjaro/Zepbound and expectations that the company remains one of the biggest beneficiaries of the GLP-1 boom.
• Positive Sentiment: New coverage also noted that President Trump disclosed Eli Lilly stock purchases, which may have helped sentiment by signaling high-profile confidence in the company as Medicare policy developments support broader GLP-1 coverage. Article Title
• Positive Sentiment: The company also received a reputational boost from a report saying Eli Lilly topped prominent rankings on pharma R&D performance, reinforcing the view that Lilly’s pipeline and innovation engine remain among the strongest in large-cap pharma. Article Title
• Positive Sentiment: Lilly announced it completed a key olomorasib drug-interaction study, helping clarify the next steps for its KRAS pipeline and keeping investor focus on longer-term oncology upside. Article Title
• Neutral Sentiment: Multiple pieces also framed Lilly as a top name in the “silver economy” and a long-term compounder, which supports the stock’s premium valuation but does not add a fresh near-term catalyst.
• Negative Sentiment: The main negative overhang is the U.S. Supreme Court declining to hear Lilly’s appeal in a Medicaid whistleblower case, leaving a roughly $194 million judgment in place and keeping regulatory/compliance risk in focus. Article Title
• Negative Sentiment: Competitive pressure is also a concern, with reports that Novo Nordisk’s oral Wegovy continues to lead Lilly’s rival in the developing pill market, reminding investors that obesity-drug growth may face tougher competition ahead.

Analysts Set New Price Targets

Several equities research analysts have weighed in on LLY shares. Barclays increased their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Guggenheim restated a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Scotiabank restated an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Daiwa Securities Group raised their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,218.33.

Eli Lilly and Company Trading Up 3.0%

The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The business’s fifty day moving average is $940.00 and its 200 day moving average is $999.39. The firm has a market capitalization of $958.39 billion, a price-to-earnings ratio of 36.15, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same period last year, the business posted $3.34 earnings per share. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts predict that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $25,000. Osbon Capital Management LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $25,000. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $30,000. Miller Global Investments LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $33,000. Finally, E Fund Management Hong Kong Co. Ltd. increased its stake in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.